Better Artificial Intelligence Stock: Astera Labs vs. NVIDIA

The article argues NVIDIA is the better buy for 2026, citing NVIDIA’s $215.9B FY revenue (+65.5% YoY) and $120.1B net income, alongside a valuation premium gap versus Astera Labs (Forward P/E 24.2x vs 67.0x; P/S 18.1x vs 40.8x). Astera Labs is highlighted for strong growth (FY revenue $852.5M, +115.1% YoY; Q2’26 revenue $392.4M, +104% YoY) but with higher concentration risk (one customer >70% of revenue) and valuation stretch. The main risks for NVIDIA include U.S. export controls and intensified competition/internal AI hardware, while Astera Labs faces customer-driven order volatility and possible trade restrictions impacting manufacturing.

Analysis

NVDA is the cleaner beneficiary of the AI capex cycle because it captures both unit growth and platform share, while ALAB is a narrower toll collector on data movement. That matters as the build-out shifts from first-wave cluster deployment to optimization: networking spend grows, but it is still downstream of compute purchases and therefore more exposed to hyperscaler budget timing. In a pause in AI spending, ALAB's revenue growth can decelerate far faster than the market expects, while NVDA retains pricing power through software, system pull-through, and product-cycle upgrades.

The key second-order risk for ALAB is that customer concentration is not just concentration; it is architecture dependence. If a large cloud customer decides to redesign around in-house silicon or multi-source connectivity, the hit is not merely lost volume but lower bargaining power on future sockets and standards. NVDA faces its own pressure from export controls and custom ASIC efforts by large customers, but those are slower-moving threats; over the next 1-3 months the bigger variable is whether hyperscaler capex prints confirm acceleration or merely rotation.

The market may be missing that the 'picks-and-shovels' premium on ALAB can compress quickly if AI infrastructure spend becomes more disciplined. Conversely, NVDA's lower forward multiple versus ALAB likely reflects mature-scale skepticism rather than a broken story, and the next platform transition can still re-rate earnings power if Rubin adoption lands well. The thesis is falsified if NVDA guides materially below current growth assumptions or if ALAB shows meaningful customer diversification without margin dilution over the next two quarters.

Key Decisions for Investors

• Long NVDA / short ALAB as a relative-value pair into the next AI capex update cycle; favor NVDA because it has broader end-market optionality and less customer-specific redesign risk.
• Buy NVDA on pullbacks ahead of the next platform transition, using earnings revisions as the trigger; risk/reward is better if the market keeps paying a discount for scale while revisions stay up.
• Avoid chasing ALAB after strength unless the next filing shows top-customer dependence falling materially; otherwise treat it as a high-beta derivative on hyperscaler spending, not a core compounder.
• If you need a hedge for NVDA supply-chain or export-control risk, pair it with a small short in MSFT or AMZN only if evidence emerges that internal silicon is displacing merchant GPUs; otherwise the catalyst is too slow.
• Set a watch item on hyperscaler capex commentary and AI networking budgets over the next 1-3 months; if those comments soften, rotate out of ALAB first, not NVDA.